Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups

MT Newswires Live2025-11-13

(Corrects the headline and first paragraph to clarify there was no statistical significance in meeting endpoints.)

Niagen Bioscience (NAGE) said Wednesday that a clinical trial showed that daily supplement of its patented nicotinamide riboside Niagen did not show "statistically significant differences" in meeting primary or secondary endpoints in patients with long COVID-19 relative to placebo groups.

The 58-participant placebo-controlled 24-week study showed that the supplement increased NAD+ co-enzyme levels up to 3.1-fold and improved functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some individuals, the company said.

The study's inconclusive results were "likely due to the small sample size and high dropout rates," the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment